Power Mall warning letter
This article was originally published in The Tan Sheet
Executive Summary
FDA cites claims that Power Mall's Q Gel dietary supplement can "provide effective treatment of heart disease, chronic fatigue and support during cancer treatment" in a recent warning letter to the company. A review of the firm's website also finds that Gastro Enzymes claims to treat "ulcers, colitis, duodenal ulcer, gastritis, unexplained blood in urine..." the agency adds. Other products cited in the letter for making drug claims include Taurine Spray, AsmaSpray,D-Lenolate,Curcumin98,OxySorb, Eskimo 3 Fish Oil and AtaXanthin. FDA allows Power Mall 15 working days to notify the agency of the steps it is taking to correct the violations...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.